Amgen vs Xiaomi: Founders, CEOs and History
Amgen was founded in 1980 by George B. Rathmann, William K. Bowes Jr. and is led by Robert A. Bradway. Xiaomi was founded in 2010 by Lei Jun, Lin Bin and is led by Lei Jun.
Company facts
Founders
Amgen
George B. Rathmann
Amgen, originally incorporated as Applied Molecular Genetics, was founded in 1980 not by a single scientist, but by a calculated syndicate of venture capitalists and academics trying to commercialize the brand-new science of recombinant DNA.
William K. Bowes Jr.
William K. Bowes Jr. Was the venture capital strategist whose vision catalyzed Amgen's formation.
Xiaomi
Lei Jun
Lei Jun founded Xiaomi in 2010 and is its chairman and CEO. He set the company's early strategy of selling well-specified phones online at low prices, built the MIUI user community, and later led Xiaomi's 2018 Hong Kong listing.
Lin Bin
Lin Bin co-founded Xiaomi in 2010 and served as its president, overseeing early phone development and supply-chain relationships. He handed the president role to others in 2019 and continued as vice chairman of the board.
CEOs and their tenures
Amgen
- George B. Rathmann1980–1988
Chief Executive Officer
George Rathmann, a physical chemist who had run research and development at Abbott Laboratories, was named Amgen's first chief executive in 1980 and worked from a small trailer so that laboratory space could go to scientists.
Source - Gordon M. Binder1988–2000
Chief Executive Officer
Gordon Binder joined Amgen as chief financial officer in 1982 and led its June 1983 initial public offering.
Source - Kevin W. Sharer2000–2012
Chief Executive Officer
Kevin Sharer joined Amgen in 1992 as president and chief operating officer and became chairman and chief executive in 2000.
Source - Robert A. Bradway2012–present
Chairman and Chief Executive Officer
Robert Bradway became chief executive on May 23, 2012, succeeding Kevin Sharer as the fourth CEO in Amgen's history, and added the chairmanship at the start of 2013.
Source
Xiaomi
- Lei Jun2010–present
Founder, Chairman and CEO
Sets Xiaomi's product and ecosystem strategy and leads the EV business.
Source - Lin Bin2010–present
Co-founder and Vice Chairman
Co-founded Xiaomi with Lei Jun and served as president during its early growth before moving to the vice chairman role.
Source - Lu Weibing2022–present
President
Runs day-to-day operations of the group, having earlier led the Redmi brand and international business.
Source
Timeline: Amgen and Xiaomi side by side
1980Amgen
Applied Molecular Genetics is incorporated
Applied Molecular Genetics (AMGen) was incorporated on April 8, 1980 in Thousand Oaks, California, as the idea of venture capitalist William K. Bowes Jr. and a group of scientific collaborators.
1983Amgen
Nasdaq listing and the erythropoietin clone
Amgen completed its initial public offering on June 17, 1983, raising nearly US$40 million under chief financial officer Gordon Binder, and formally shortened its name to Amgen.
1984Amgen
Kirin-Amgen joint venture formed
Amgen and Kirin Brewery Company of Japan formed Kirin-Amgen in 1984 as a joint venture for the worldwide commercialization of erythropoietin.
1985Amgen
G-CSF cloned, leading to Neupogen
While Fu-Kuen Lin's team worked on erythropoietin, researcher Larry Souza and his group cloned and expressed human granulocyte colony-stimulating factor in 1985.
1989Amgen
FDA approves Epogen
The FDA approved Epogen (epoetin alfa) on June 1, 1989 for anemia in patients with chronic kidney failure on dialysis. It was the first commercial recombinant human erythropoietin. Epogen's U.S.
1991Amgen
Neupogen approved, giving Amgen a second franchise
The FDA approved Neupogen (filgrastim) in February 1991. By stimulating white blood cell production it reduced the risk of infection in cancer patients with chemotherapy-induced neutropenia.
1991Amgen
Amgen wins the erythropoietin patent fight
On March 6, 1991 the U.S. Court of Appeals for the Federal Circuit upheld the Kirin-Amgen erythropoietin patent and ruled against Genetics Institute in Amgen v. Chugai Pharmaceutical and Genetics Institute.
2001Amgen
FDA approves Aranesp, the longer-acting EPO
Aranesp (darbepoetin alfa), an erythropoietin analogue with modified glycosylation and a longer half-life, was approved in 2001. Less frequent dosing than Epogen improved convenience and gave Amgen a newer, higher-priced product to migrate patients toward.
2002Amgen
US$16 billion Immunex acquisition brings Enbrel in-house
Amgen completed its acquisition of Immunex Corporation on July 16, 2002, the largest biotechnology deal to that point at about US$16 billion in stock and cash.
2010Amgen
Prolia and XGEVA create the bone health franchise
The FDA approved Prolia (denosumab) for postmenopausal osteoporosis in June 2010 and XGEVA, the same molecule at a higher dose, for prevention of skeletal-related events in cancer patients in November 2010.
2010Xiaomi
Xiaomi Founded
Lei Jun and seven co-founders establish Xiaomi in Beijing and release the MIUI Android software.
2011Xiaomi
Mi 1 Launches
Xiaomi launches its first smartphone, sold online.
2014Xiaomi
India Entry and $45B Valuation
Xiaomi enters India and raises funding at a reported $45B valuation.
2018Xiaomi
Hong Kong IPO
Xiaomi lists on the Hong Kong Stock Exchange under stock code 1810 with a weighted voting rights structure.
2019Amgen
US$13.4 billion purchase of Otezla from Celgene
Amgen agreed in August 2019 to buy worldwide rights to Otezla (apremilast) from Celgene for US$13.4 billion in cash, or about US$11.2 billion net of the present value of US$2.2 billion of anticipated future cash tax benefits, and closed on November 21, 2019.
2020Amgen
Amgen joins the Dow Jones Industrial Average
Amgen replaced Pfizer in the Dow Jones Industrial Average on August 31, 2020, becoming one of the thirty components in the index. Inclusion recognized the scale Amgen had reached and added passive demand from Dow-tracking funds.
2021Xiaomi
EV Entry Announced
Xiaomi announces it will build electric vehicles and sets up a dedicated EV subsidiary.
2021Xiaomi
Acquired DeepMotion
Xiaomi acquired DeepMotion for $77 million. Autonomous-driving technology company acquired to support Xiaomi's EV program.
2023Amgen
US$27.8 billion Horizon Therapeutics acquisition closes
Amgen completed the acquisition of Horizon Therapeutics plc on October 6, 2023 for US$116.50 per share in cash, an equity value of about US$27.8 billion, after settling FTC litigation with a behavioral consent decree.
2024Amgen
Imdelltra becomes the first T-cell engager for small cell lung cancer
The FDA granted accelerated approval to tarlatamab, sold as Imdelltra, on May 16, 2024 for extensive stage small cell lung cancer that has progressed on or after platinum-based chemotherapy.
2024Xiaomi
SU7 Launch
Xiaomi launches the SU7 electric sedan in March 2024 and begins deliveries.
2025Amgen
VESALIUS-CV extends the Repatha case to primary prevention
In November 2025 Amgen reported Phase 3 VESALIUS-CV results in more than 12,000 patients with atherosclerosis or diabetes but no prior heart attack or stroke.
2025Xiaomi
Record Year and YU7 Launch
Xiaomi launches the YU7 SUV, delivers 411,082 vehicles, and reports FY2025 revenue of ~$63.6B (RMB457.3B).
2026Amgen
Medicare price setting reaches Enbrel and Otezla
Enbrel's negotiated Medicare price under the Inflation Reduction Act took effect on January 1, 2026, after it was named in the first round of ten drugs selected for negotiation.
2026Xiaomi
Memory Costs Hit Profit
Q1 revenue falls 10.9% to ~$13.8B (RMB99.1B) and Q2 revenue falls 6.1% to ~$15.1B (RMB108.9B) as memory-chip costs squeeze margins.
Acquisitions
Amgen
- Horizon Therapeutics plc2023$27.8B
- ChemoCentryx, Inc.2022$3.7B
- Five Prime Therapeutics2021$1.9B
- Celgene Otezla Business2019$13.4B
- Onyx Pharmaceuticals, Inc.2013$10.4B
- DeCODE Genetics2012$415M
Questions about Amgen vs Xiaomi
Who is the CEO of Amgen Inc. and Xiaomi Corp.?
Amgen Inc. is led by Robert A. Bradway and Xiaomi Corp. is led by Lei Jun. Both serve as the top executive responsible for the company's strategy, operations, and financial performance.
When was Amgen Inc. founded vs Xiaomi Corp.?
Amgen Inc. was founded in 1980 — 30 years before Xiaomi Corp., which was founded in 2010. Amgen Inc.'s longer operating history gives it a deeper track record but also potentially more institutional inertia compared to the younger Xiaomi Corp..
How many employees does Amgen Inc. have compared to Xiaomi Corp.?
Amgen Inc. employs approximately 31,500 people, while Xiaomi Corp. employs approximately 56,531. Xiaomi Corp. has the larger workforce at 56,531 employees, compared to Amgen Inc.'s 31,500. A higher headcount does not necessarily imply greater efficiency — it often reflects differences in business model (e.g., manufacturing vs. software).
Where are Amgen Inc. and Xiaomi Corp. headquartered?
Amgen Inc. is headquartered in United States and Xiaomi Corp. is headquartered in China. Their different home markets mean they may face different regulatory frameworks, tax regimes, and currency exposure.
Who founded Amgen Inc. and Xiaomi Corp.?
Amgen Inc. was founded by George B. Rathmann, William K. Bowes Jr.. Xiaomi Corp. was founded by Lei Jun, Lin Bin.
Which company has a longer operating history — Amgen Inc. or Xiaomi Corp.?
Amgen Inc. has been operating for approximately 46 years, making it the more established of the two companies. Xiaomi Corp. has been in operation for around 16 years. A longer operating history often signals greater institutional resilience and brand recognition, though it can also mean slower adaptation to new market conditions.
Figures come from each company's filings and the sources linked beside them. Amounts reported in another currency are shown in US dollars at an approximate rate and marked with ~. Back to the Amgen vs Xiaomi overview